Sandoz: Pioneering Access to Medicines as a Global Leader in Generics and Biosimilars

Sandoz, a Swiss pharmaceutical company, has established itself as a global leader in the development and distribution of generic and biosimilar medicines. With a mission to “pioneer access to medicines for patients globally,” the company plays a critical role in ensuring affordability and availability of essential treatments across the world.

Historical Foundations and Evolution

Founded in 1886 by Alfred Kern and Edouard Sandoz in Basel, Switzerland, the company initially focused on the production of dyes and pharmaceuticals. Over the decades, Sandoz evolved into a major player in the pharmaceutical industry, eventually becoming a division of Novartis. In 2003, Novartis consolidated its generics businesses under the Sandoz name, and in 2023, Sandoz was spun off as an independent entity. This transition marked a new era for the company, allowing it to focus exclusively on its core mission of expanding access to medicines.

Global Operations and Strategic Focus

Today, Sandoz operates with a strong emphasis on generic and biosimilar medicines, which are critical in reducing healthcare costs and improving patient outcomes. The company’s headquarters are in Basel, Switzerland, with key operational centers in Germany, Czechia, and Spain. Sandoz’s extensive portfolio includes a wide range of medications, from organ transplant treatments to antipsychotics and migraine therapies, reflecting its long history of innovation in specialized pharmaceuticals.

As a leader in biosimilars, Sandoz is at the forefront of developing high-quality, cost-effective alternatives to biologic medicines. These biosimilars are essential in making life-saving treatments more accessible, particularly in regions where healthcare resources are limited.

Recent Developments and Industry Impact

In recent years, Sandoz has highlighted the growing importance of biosimilars in addressing global healthcare challenges. According to industry insights, the expiration of over $300 billion in biologic patents over the next decade presents significant opportunities to enhance medicine affordability. Sandoz has been actively involved in this space, launching new biosimilar medicines and advocating for policies that support market transparency and patient access.

In 2025